AdvantiGen Biosciences
Howard Teeter is a highly experienced professional currently serving as the CFO at AdvantiGen Biosciences. With a background in chemistry, Howard has held various leadership positions in companies such as BIOLOGY BASED PHARMACEUTICALS LLC and Anteco Pharma. Howard's extensive experience includes roles such as President & Managing Partner at Anteco Pharma and Senior VP Operations at Intergen Company. Howard has also been involved in various boards, including the Columbia County Economic Development Corporation and the Workforce Development Board of South Central Wisconsin. With a strong educational foundation from University of Notre Dame and Manchester University, Howard brings a wealth of knowledge and expertise to the organizations Howard is a part of.
This person is not in any teams
AdvantiGen Biosciences
AdvantiGen has discovered and validated a new Immune-Checkpoint (IC) target on T-cell for Immuno-Oncology; a market forecasted to grow to > $ 155 Billion by 2031. AdvantiGen ADVAN-1 monoclonal antibody (mAbs) program has delivered a set of mAbs modulating the interaction between this new IC target and its ligand(s), thus restoring the ability of the T cell to kill the cancer cells; the hallmark of an Immune Checkpoint Inhibitors (ICI). AdvantiGen has also shown that its novel target interacts with many cancer cell types, hinting at clinical relevance of the target in both solid tumors, such as skin, kidney, breast, colorectal, lung and liver cancers as well as blood cancers, such T cell Lymphoma and AML.